How to reach more patients faster: the promise of international collaboration and shared regulatory approval pathways
Panel discussion summary
International collaboration is a key element of the Swiss innovation landscape. Early support to build bridges between experts from different countries and collaborative international regulatory approval pathways, such as ACCESS and Orbis, result in faster access for patients. In this panel discussion we will share different perspectives and experiences and provide insights into the opportunities created for patients.
Date, time and room information
Global Village track: May 5, 15:30 - 16:15, room Verseau
Moderation
| Name | Position | Institution |
|---|---|---|
| Eveline Trachsel | Head of Medicinal Product Authorisation and Vigilance | Swissmedic, Swiss Agency for Therapeutic Products |
Panelists
| Name | Position | Institution |
|---|---|---|
| Corinne Wenger | Head of Regulatory Affairs | Roche Pharma (Schweiz) AG |
| Sabine Ledderhose | Head of Regulatory Affairs | Astra Zeneca |
| Sergio Cantoreggi | Chief Scientific Officer | Sintetica S.A. |
Swissmedic, Swiss Agency for Therapeutic Products
Swissmedic, the Swiss Agency for Therapeutic Products, is the regulatory and supervisory authority for therapeutic products. Swissmedic ensures that the therapeutic products it approves in Switzerland are of impeccable quality, effective and safe. In doing so it makes a significant contribution to safeguarding human and animal health.
Further information
Host and event manager:
Logistics and marketing partner:
